China’s National Medical Products Administration has accepted an application for the approval of denosumab copy biological HLX 14.- Shanghai Henlius Biotech
China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), has accepted an application for the approval of denosumab copy biological HLX 14. China-based… read more.